Skip to content
Home/Companies/Biotech/CV6 Therapeutics
CV6 Therapeutics

CV6 Therapeutics

Biotech·UK·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns CV6 Therapeutics?

CV6 Therapeutics is a British Biotech company, currently owned by Clarendon Fund Managers since 2022.

Hand-verified · updated 2026-06-30

Open JSON · CC-BY
Clarendon Fund Managers
Investor
Clarendon Fund Managers
Co-Fund NI · 2012 · VC

Key facts

HQUK
SectorBiotech
StatusActive
Websitecv6t.com

More from Co-Fund NI

Other portfolio companies in the same fund.

GenoME Diagnostics
GenoME Diagnostics
Active
BiotechUK· 2023
Kinsetsu
Active
SaaSUK· 2023
Amply
Amply
Active
BiotechUK· 2022
Angoka
Angoka
Active
CybersecurityUK· 2022
Aramune Technologies
Aramune Technologies
Active
BiotechUK· 2022
Modern Democracy
Modern Democracy
Active
SaaSUK· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns CV6 Therapeutics?

CV6 Therapeutics is currently owned by Clarendon Fund Managers, through Co-Fund NI, since 2022.

When did Clarendon Fund Managers acquire CV6 Therapeutics?

Clarendon Fund Managers acquired CV6 Therapeutics in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue